Abstract: Cutaneous reactions associated with interferons (IFNs) treatment are either localized or generalized. The most common presentation of localized reactions at IFNs injection site is usually an erythematous patch or plaque. Local leukocytoclastic vasculitis presenting with cutaneous necrosis is extremely rare. We report a 19-year-old man with hepatitis B who had local leukocytoclastic vasculitis induced by interferon-gama injection at the injection site. After changing the injection sites and using the combined treatment of prednisone and colchicine, the previous lesion healed and no other cutaneous lesion occurred. We also made a mini review of such cases.
INTRODUCTION
Interferons (IFNs) are a family of five groups of proteins (alpha, beta, gamma, tau, and omega) produced by most cells in response to certain viruses, bacteria, antigens, mitogens, and ribonucleic acid, etc. 1 Their functions include anti-virus, anti-cellular proliferation, immunoregulation, oncogene inhibition, cellular differentiation, and antiangiogenesis. 1 Unfortunately, patients receiving IFNs treatment always experience side effects. Common flu-like symptoms and cutaneous reactions have been reported. Occasionally, local skin reactions at the injection site can occur, but skin necrosis is not frequent. Herein, we describe a patient with hepatitis B virus infection who presented with cutaneous necrosis diagnosed as leukocytoclastic vasculitis (LCV) at the injection site of interferon gamma (IFN-γ).
The patient showed excellent response to the combined treatment of prednisone and colchicine.
CASE REPORT
A 19-year-old man was referred to our clinic with a 3-week history of progressively painful erythema and necrosis on the ab- The typical clinical presentation of localized reactions at injection sites is usually an ill-defined, pruritic, erythematous patch or plaque, which is generally transient and does not require treatment.
Skin ulceration and necrosis seem to be an infrequent complication that occur in less than 4% of individuals receiving interferon beta (IFN-β) and appear to be less frequent with interferon alpha (IFN-α) and IFN-γ. 2 Rasokat et al. 3 They reported that the necrosis was absent for age, sex, or underlying disease predominance, and was usually unrelated to the dose or frequency of administration as well as the injection location.
Necrotic ulcers could be single or multiple with various diameters.
They mostly developed on the base of an inflammatory plaque that occurred after the onset of treatment varying from weeks to years, usually being months. The major clinical manifestations of our patient who presented with two cutaneous ulcers developing on the base of the erythema were consistent with the previous studies.
The major histopathologic features of a patient with necrotic ulceration at the IFN injection site included perivascular dermatitis with lymphocytic infiltration and thrombosis of deep vessels, and in rare instance, lobular panniculitis. 5 LCV, as our patient presented, was exceptionally rare. To our knowledge, only 5 cases, including the present one, have been reported (Table 1) . [6] [7] [8] [9] Among them, 3
were treated with IFN-α, and the other two were treated with IFN-β and IFN-γ, respectively. The mean age was 46.6 years, with female/ male ratio of 4 to 1. The mean incubation time was 10.2 ± 6.7 weeks.
Three cases had non-ulcerative lesions and 2 cases, including our case, developed ulcerative necrosis. Interestingly, the two patients 
